Ligand Pharmaceuticals Incorporated (LGNYZ)

OTCMKTS · Delayed Price · Currency is USD · Rights
0.0468
0.00 (0.00%)
At close: Jun 3, 2026
Market Cap4.08B +82.8%
Revenue (ttm)268.09M +60.4%
Net Income124.45M
EPS6.13
Shares Out n/a
PE Ratio32.82
Forward PE21.64
Dividend0.00 (1.65%)
Ex-Dividend DateDec 29, 2025
Volume1,000
Open0.0468
Previous Closen/a
Day's Range0.0468 - 0.0468
52-Week Range0.0061 - 0.0900
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateMay 7, 2026

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]

Industry Pharmaceutical Preparations
Sector Healthcare
Founded 1987
Employees 47
Stock Exchange OTCMKTS
Ticker Symbol LGNYZ